Prostate Cancer Roundtable Calls for Quality-Of-Life Endpoints

At it’s December 9, 2013 meeting, the Prostate Cancer Roundtable addressed the need for quality of life endpoints based on patient-reported outcomes data, in pivotal trials of all biologic and pharmaceutical agents being assessed for regulatory approval in the treatment of prostate cancer with a primary endpoint of improved survival.

The Roundtable voted unanimously to include a statement to this effect in the updated Policy Statement.  You may read the press release here: New Addition to the Prostate Cancer Roundtable Policy Agenda Addresses Quality of Life Endpoints

You can find the Prostate Cancer Roundtable policy agenda here, updated December 2013.